Delivery Order SPE2DB22D2206-SPE2DB25FJM69
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $33,849.19 delivery order for Wezlana 90 mg/ml syringes, with an ultimate completion date of August 4, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $74,758.45 by the Defense Logistics Agency on August 14, 2025, for the supply of Wezlana 90 mg/mL syringes. This competitively awarded, firm fixed-price contract carries an ultimate completion date of August 15, 2025, and will be performed at the contractor's Conshohocken facility. The award represents a child delivery order issued under...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $48,074.88 delivery order for Wezlana 90 mg/ml syringes on July 31, 2025, with an ultimate completion date of August 1, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the awardee's facility in Conshohocken, Pennsylvania. The delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $37,404.32 to AmerisourceBergen Drug Corp for the supply of Wezlana 90 mg/mL syringes. This firm fixed-price contract, awarded on August 1, 2025, with an ultimate completion date of August 4, 2025, represents a competitively awarded procurement with no set-aside designation. The work will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen...
- The Defense Logistics Agency awarded a $15,801.47 delivery order to AmerisourceBergen Drug Corp for Wezlana 90 mg/mL syringes on August 18, 2025, with completion targeted for August 19, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order valued at $73,246.58 to AmerisourceBergen Drug Corp for the supply of Wezlana 90 mg/ml syringes, with a completion date of July 31, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded on July 30, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor for federal medical procurement,...
- The Defense Logistics Agency awarded a $30,488.88 delivery order to AmerisourceBergen Drug Corp for Wezlana 90 mg/mL syringes. The contract, awarded on July 28, 2025, with an ultimate completion date of July 29, 2025, utilizes firm fixed price pricing with no set-aside designation. Performance will take place at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,735.28 to AmerisourceBergen Drug Corp for Wezlana 90 mg/ml syringes. This firm fixed-price delivery order, issued on August 5, 2025, represents a non-competitive award executed under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 6,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $23,540.76 to AmerisourceBergen Drug Corp for the supply of Wezlana 90 mg/mL syringes. This competitive delivery order, issued on August 7, 2025, with an ultimate completion date of August 8, 2025, utilizes firm fixed pricing and carries no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a major pharmaceutical distributor and critical federal...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $20,643.53 by the Defense Logistics Agency (DLA) on August 13, 2025, with an ultimate completion date of August 14, 2025. The delivery order, issued under contract 4569085162, is for Wezlana 90 mg/ml syringes and represents a non-set-aside, competitively awarded contract with firm fixed pricing. This award is a child contract issued under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJM69Delivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $17,843.93 for Wezlana 90 mg/ml syringes to be delivered to Conshohocken, Pennsylvania. This competitively awarded, firm fixed-price contract with an ultimate completion date of August 20, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The SPE2DX prime IDV, valued at $999,999,999.00 through December 2026, serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement needs across the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's federal contract portfolio demonstrates extensive capability in delivering specialty medications, brand-name and generic drugs, vaccines, and related medical supplies across multiple therapeutic domains. No set-aside designation applied to this award, indicating it was awarded through open competition consistent with the company's track record of competitive federal procurements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.8k | 8/19/25 |